Jan. 12 at 5:09 PM
$CMPX Comservatively assuming 70 percent shot at FDA approval of tovecimig for second line therapy for BLT, intrinsic value of CMPX is
$7 to
$14 at a healthy 15 percent discount rate. No assumed expanded use cases or even frontline treatment of BLT. Also zero value assumed for very promising pipeline assets. Bought more earlier today as market price should catch up with intrinsic value in due time. I actually think FDA approval might well be 80 percent given primary endpoint and very low death rate suggests OS could prove groundbreaking. Nothing certain — reflective of my 20 percent hedge as there is nothing that can ever be assumed a lock.
